General Archive
-
News releases
Heptares secures funding
Heptares has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip…
-
News releases
UK Drug Discovery Consortium symposium
‘Imperial College London‘, ‘Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research’, ‘ Drug Discovery Unit,…
-
News releases
MRCT licence rights to develop potential novel immunotherapy
Centocor Ortho Biotech have signed agreements for the development of a novel immunotherapy targeting respiratory disease. The potential therapy was…
-
News releases
MRCT and Biolex Therapeutics complete successful collaborations
MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in Non-Hodgkin’s lymphoma and rheumatoid arthritis. Biolex…
-
News releases
Intellect Neurosciences and MRCT reach antibody milestone
The milestone is an important stage in the collaborative efforts to humanize Intellect’s lead antibody IN-N01 necessary for creating a…
-
News releases
Development Gap Fund extended
The MRC has approved a further £6 million of funding for a continuation of the MRCT Development Gap Fund (DGF).…
-
News releases
New Tysabri data released
Biogen Idec and Elan Corporation, plc have announced new data on the global utilization, safety and overall patient exposure of…
-
News releases
How malaria parasites escape blood cells
a collaboration between teams at the MRC’s National Institute for Medical Research and MRCT’s Drug Discovery Group has produced a…
-
News releases
Intellect Neurosciences and MRCT to humanize antibodies for AD
MRCT will use its proprietary technology and advanced know-how to humanize Intellect’s beta-amyloid specific, monoclonal antibodies for the treatment of…
-
News releases
Organon and MRC Technology sign antibody development agreement
The collaborative agreement will cover development of a humanised antibody for the treatment of certain forms of cancer. The Therapeutic…
-
News releases
MRCT to humanize antibody to treat SLE
SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT…
-
News releases
MRCT to humanize antibody to treat AD
MRC Technologyand BioArctic Neuroscience have signed an collaborative research agreement to humanise a mouse antibody under development with BioArctic for…